Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy

Veure altres versions (1)

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disorder caused by mutations in the dystrophin gene. Antisense-mediated exon skipping is one of the most promising approaches for the treatment of DMD but still faces personalized medicine challenges as different mutations found in DMD pati...

Descripció completa

Dades bibliogràfiques
Autors principals:	Goyenvalle, A, Wright, J, Babbs, A, Wilkins, V, Garcia, L, Davies, K
Format:	Journal article
Idioma:	English
Publicat:	2012

Ítems similars

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.
per: Goyenvalle, A, et al.
Publicat: (2012)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
per: Goyenvalle, A, et al.
Publicat: (2011)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
per: Goyenvalle, A, et al.
Publicat: (2010)

Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
per: Goyenvalle, A, et al.
Publicat: (2011)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
per: van Ommen Gert-Jan B, et al.
Publicat: (2008-12-01)

Upgrading U7snRNA To Complete Efficient Rescue of Dystrophin by Exon-Skipping in DMD Patients
per: Goyenvalle, A, et al.
Publicat: (2009)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping
per: Goyenvalle, A, et al.
Publicat: (2012)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
per: Goyenvalle, A, et al.
Publicat: (2012)

Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.
per: Goyenvalle, A, et al.
Publicat: (2009)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery.
per: Eckenfelder, A, et al.
Publicat: (2012)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery
per: Agathe Eckenfelder, et al.
Publicat: (2012-01-01)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.
per: Goyenvalle, A, et al.
Publicat: (2011)

AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy
per: Le Hir, M, et al.
Publicat: (2013)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy
per: Goyenvalle Aurélie, et al.
Publicat: (2011-02-01)

Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice
per: Philippine Aupy, et al.
Publicat: (2020-06-01)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
per: van Ommen Gert-Jan B, et al.
Publicat: (2007-07-01)

From diagnosis to therapy in Duchenne muscular dystrophy
per: Babbs, A, et al.
Publicat: (2020)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
per: Guiraud, S, et al.
Publicat: (2019)

New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy.
per: Aoki, Y, et al.
Publicat: (2012)

Targeting Duchenne muscular dystrophy by skipping DMD exon 45 with base editors
per: Michael Gapinske, et al.
Publicat: (2023-09-01)

Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis
per: Yuko Shimizu-Motohashi, et al.
Publicat: (2018-06-01)

Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in mice
per: Christina Gedicke‐Hornung, et al.
Publicat: (2013-05-01)

Possibility of exon skipping therapy for Duchenne muscular dystrophy in Russian patients: present and future
per: E. V. Zinina, et al.
Publicat: (2024-09-01)

Progress in therapy for Duchenne muscular dystrophy.
per: Fairclough, R, et al.
Publicat: (2011)

Progress in therapy for Duchenne muscular dystrophy
per: Fairclough, R, et al.
Publicat: (2011)

Utrophin in the therapy of Duchenne Muscular Dystrophy
per: Potter, A, et al.
Publicat: (2006)

Exon skipping peptide-pmos for correction of dystrophin in mouse models of duchenne muscular dystrophy
per: Betts, C, et al.
Publicat: (2014)

Regenerative biomarkers for Duchenne muscular dystrophy
per: Guiraud, S, et al.
Publicat: (2019)

Duchenne Muscular Dystrophy
per: J Gordon Millichap
Publicat: (1989-05-01)

Regenerative biomarkers for Duchenne muscular dystrophy
per: Simon Guiraud, et al.
Publicat: (2019-01-01)

Therapeutic approaches for Duchenne muscular dystrophy
per: Roberts, TC, et al.
Publicat: (2023)

Duchenne muscular dystrophy: recent insights in brain related comorbidities
per: Cyrille Vaillend, et al.
Publicat: (2025-02-01)

Utrophin upregulation in Duchenne muscular dystrophy.
per: Hirst, R, et al.
Publicat: (2005)

Challenges for antisense oligonucleotide-based therapeutics, in particular for exon 51-skipping in Duchenne muscular dystrophy
per: Aoki, Y, et al.
Publicat: (2011)

CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy
per: Harry Wilton-Clark, et al.
Publicat: (2023-09-01)

Newborn screening of duchenne muscular dystrophy specifically targeting deletions amenable to exon-skipping therapy
per: Pablo Beckers, et al.
Publicat: (2021-02-01)

Upper limb disease evolution in exon 53 skipping eligible patients with Duchenne muscular dystrophy
per: Charlotte Lilien, et al.
Publicat: (2021-10-01)

Evaluation of 2’-Deoxy-2’-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
per: Silvana M G Jirka, et al.
Publicat: (2015-01-01)

Duchenne muscular dystrophy - past, present and future
per: Davies, K
Publicat: (2002)

Pharmacological advances for treatment in Duchenne muscular dystrophy
per: Guiraud, S, et al.
Publicat: (2017)